Mendus AB (publ) (STO:IMMU)

Market Cap	407.86M
Revenue (ttm)	5.05M
Net Income (ttm)	-128.40M
Shares Out	50.36M
EPS (ttm)	-2.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,257
Average Volume	32,553
Open	8.12
Previous Close	8.14
Day's Range	8.00 - 8.30
52-Week Range	6.51 - 11.26
Beta	0.79
RSI	52.89
Earnings Date	Feb 13, 2025

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 28
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IMMU

Financial Performance

In 2024, Mendus AB's revenue was 5.05 million, a decrease of -82.28% compared to the previous year's 28.49 million. Losses were -128.40 million, 26.4% more than in 2023.